Johnson & Johnson (JNJ) Stock Forecast & Price Target

$151.62 +2.93 (+1.97%)

Closing price 04/11/2025 03:59 PM Eastern

Extended Trading

$151.68 +0.06 (+0.04%)

As of 04/11/2025 07:59 PM Eastern

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
8

Buy
10

Based on 18 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 8 have given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for JNJ.

Consensus Price Target

$171.67
13.22% Upside

According to the 18 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $171.67. The highest price target for JNJ is $215.00, while the lowest price target for JNJ is $150.00. The average price target represents a forecasted upside of 13.22% from the current price of $151.62.

Get the Latest News and Ratings for JNJ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors.

JNJ Analyst Ratings Over Time

Type	Current Forecast 4/13/24 to 4/13/25	1 Month Ago 3/14/24 to 3/14/25	3 Months Ago 1/14/24 to 1/13/25	1 Year Ago 4/14/23 to 4/13/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	8 Hold rating(s)	9 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$171.67	$171.33	$174.71	$177.31
Forecasted Upside	13.22% Upside	5.15% Upside	20.91% Upside	20.19% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold

Remove Ads

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Johnson & Johnson Stock vs. The Competition

Type	Johnson & Johnson	Medical Companies	S&P 500
Consensus Rating Score	2.61	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	13.22% Upside	21,711.68% Upside	27.84% Upside
News Sentiment Rating	Positive News See Recent JNJ News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/10/2025	Bank of America 3 of 5 stars	Tim Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$171.00 ➝ $159.00	+6.70%
4/9/2025	Morgan Stanley 3 of 5 stars	Terence Flynn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$163.00 ➝ $164.00	+12.14%
4/9/2025	The Goldman Sachs Group 3 of 5 stars	Asad Haider Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$157.00 ➝ $172.00	+15.25%
4/2/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00 ➝ $181.00	+17.10%
4/2/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
1/28/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$159.00 ➝ $166.00	+8.56%
1/24/2025	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
1/23/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$182.00 ➝ $169.00	+15.12%
1/23/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$170.00 ➝ $155.00	+5.58%
1/23/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$166.00 ➝ $152.00	+4.55%
Get the Latest News and Ratings for JNJ and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.
1/23/2025	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$170.00 ➝ $165.00	+13.49%
12/11/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$185.00 ➝ $175.00	+19.18%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$190.00	+25.12%
10/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$215.00 ➝ $215.00	+30.70%
7/23/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/23/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$160.00 ➝ $150.00	-2.75%
7/18/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$161.00 ➝ $171.00	+9.10%
7/18/2024	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$195.00 ➝ $185.00	+18.03%
7/18/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$195.00 ➝ $185.00	+18.38%
4/18/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$169.00 ➝ $170.00	+17.43%
12/1/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$167.00 ➝ $180.00	+16.39%
8/4/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$167.00 ➝ $170.00	-0.42%
7/21/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$175.00 ➝ $180.00	+5.75%
7/21/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$170.00 ➝ $175.00	+3.92%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:34 AM ET.

Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 8, 2025. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

Johnson & Johnson
Bull Case

Here are some ways that investors could benefit from investing in Johnson & Johnson:

Strong Financial Performance: Johnson & Johnson reported a quarterly revenue of $22.52 billion, exceeding analyst expectations, which indicates robust demand for its products and effective management.
Consistent Earnings Growth: The company achieved earnings per share (EPS) of $2.04, surpassing estimates by $0.05, showcasing its ability to generate profits consistently.
Stable Market Position: With a market capitalization of $362.60 billion, Johnson & Johnson is a leading player in the healthcare sector, providing a sense of stability and reliability for investors.
Low Debt Levels: The debt-to-equity ratio of 0.43 suggests that the company is not overly reliant on debt for financing, which can reduce financial risk and enhance investor confidence.
Current Stock Price: As of now, Johnson & Johnson's stock price is around $159.70, which is close to its fifty-day moving average, indicating a stable price trend that may attract investors looking for a solid entry point.

Johnson & Johnson
Bear Case

Investors should be bearish about investing in Johnson & Johnson for these reasons:

High Price-to-Earnings Ratio: With a PE ratio of 22.63, the stock may be considered overvalued compared to its earnings, which could deter value-focused investors.
Slower Growth in EPS: The company’s EPS decreased from $2.29 in the same quarter last year to $2.04, indicating a potential slowdown in profit growth, which could raise concerns among investors.
Market Volatility: The beta of 0.49 suggests that the stock is less volatile than the market, but it may also indicate limited growth potential, which could be a drawback for aggressive investors.
Competitive Pressure: Johnson & Johnson operates in a highly competitive healthcare market, which may impact its market share and profitability in the long run.
Insider Selling Activity: Recent transactions by corporate insiders, including significant share sales, may signal a lack of confidence in the company's short-term prospects, which could concern potential investors.

JNJ Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $171.67, with a high forecast of $215.00 and a low forecast of $150.00.
: 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 8 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" JNJ shares.
: According to analysts, Johnson & Johnson's stock has a predicted upside of 13.22% based on their 12-month stock forecasts.
: Over the previous 90 days, Johnson & Johnson's stock had 2 upgrades by analysts.
: Johnson & Johnson has been rated by research analysts at Argus, Bank of America, Barclays, Guggenheim, Leerink Partners, Morgan Stanley, Raymond James, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Johnson & Johnson less than other "medical" companies. The consensus rating score for Johnson & Johnson is 2.61 while the average consensus rating score for "medical" companies is 2.82. Learn more on how JNJ compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:JNJ) was last updated on 4/13/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Johnson & Johnson (JNJ) Stock Forecast & Price Target